This content delves into the pharmacotherapy pearls of ENLS Version 5.0, highlighting medication characteristics, adverse effects, and optimal pharmacotherapy strategies for acute neurological injuries. It specifically focuses on Hyperosmolar Therapy, comparing options like Mannitol and Sodium Chlor

1 views • 41 slides

In this segment of ENLS Version 5.0 Pharmacotherapy Pearls, a case study is presented focusing on hyperosmolar therapy for intracranial pressure (ICP) control in a 25-year-old male with traumatic brain injury (TBI). The patient has received multiple doses of sodium chloride and mannitol within 24 ho

0 views • 41 slides

This content elaborates on the Nebraska Geriatrics Workforce Enhancement Program, supported by HRSA, focusing on age-friendly primary care and the 4Ms approach to medication management in older adults. It addresses the objectives of understanding factors affecting drug use in the elderly, recognizin

1 views • 42 slides

Gout is a condition caused by the accumulation of urate crystals, leading to inflammation and various symptoms like acute arthritis and joint destruction. This article delves into the pathophysiology of gout, highlighting factors like hyperuricemia and crystal formation. It also discusses pharmacoth

2 views • 30 slides

Nicotine dependence is a serious issue, but there are effective pharmacotherapies available to help individuals quit smoking. Nicotine, though not a carcinogen itself, is highly addictive and rapidly delivered to the brain through tobacco products. Treatments like pharmacotherapy significantly impro

0 views • 42 slides

Unani Medicine, originating from ancient Greece, is the oldest system of human civilization practiced on earth. This traditional system focuses on fundamental principles, concept of disease, diagnosis methods, and treatment modalities using pharmacotherapy and natural components of the human body. W

0 views • 47 slides

Explore the changes in addiction concepts, DSM-V criteria, diagnostic criteria for substance use disorders, etiology, epidemiology, and treatment options including settings, pharmacotherapy, and therapeutic interventions as presented in a lecture by Dr. David Willey, MD, Substance Use Unit Director

0 views • 43 slides

This pilot study investigates the effectiveness of Z-Score Sensorimotor and Individualized Neurofeedback protocols for insomnia. Primary insomnia is defined, highlighting its impact and limitations of pharmacotherapy. Psychological treatments and challenges in service delivery are discussed, emphasi

4 views • 30 slides

The Pharmacotherapy approaches in the smoking cessation program include the use of e-cigarettes, NRT, varenicline, and nurse initiation of NRT. The E-voucher scheme is implemented to support patients in the community by providing them with pharmacotherapy under the care of Trust-based Tobacco Addict

0 views • 10 slides

Explore the risks associated with tobacco use disorder, learn about nicotine withdrawal, treatment options, and behavioral modifications for tobacco cessation. Discover the impact of tobacco on various health conditions and ways to break free from the addiction through pharmacotherapy, counseling, a

0 views • 12 slides

Learn to distinguish between STE and NSTE acute coronary syndromes in terms of diagnosis, prognosis, and treatment strategies. Understand the pathophysiological differences between ACS and chronic coronary syndromes. Gain insight into diagnostic approaches, treatment regimens, and prognosis for vari

0 views • 15 slides

In heart failure management, drugs play a crucial role in reducing preload and afterload, increasing cardiac contractility, and improving overall outcomes. Common drug classes include diuretics, aldosterone antagonists, ACE inhibitors, ARBs, beta-blockers, and vasodilators. These medications help al

0 views • 8 slides

This comprehensive review discusses the pharmacotherapy options for Non-Alcoholic Fatty Liver Disease (NAFLD), covering topics such as sub-classification of NAFLD, proposed risk stratification, non-invasive measures for assessing liver fibrosis, and the NAFLD Activity Score (NAS). Anita Eftekharzade

0 views • 44 slides

Overview of pharmacological treatment options for Parkinson's disease and related conditions like choreatic dyskinesias, spastic disorders, and myasthenia gravis. Describes the degenerative process of Parkinson's disease, its symptoms, and the pharmacological interventions targeting dopamine deficit

0 views • 26 slides

This presentation focuses on building the capacity of prescribing clinicians in behavioral health settings to integrate best practices for prescribing tobacco cessation pharmacotherapy into standard care delivery. It includes goals, objectives, an agenda, and valuable information on tobacco dependen

0 views • 32 slides

This project, supported by HRSA, provides valuable information on opioid addiction treatment, including medication options, effective interventions, and important considerations. Key topics covered include medication treatment, disclosures, medications for opioid use disorder, euphoria, and pharmaco

0 views • 24 slides

This presentation by Dr. Roger D. Weiss discusses the integration of pharmacotherapy and behavioral therapy in treating patients with substance use disorders. It emphasizes the goals of behavioral therapy alongside medication treatment, focusing on medication adherence, defining and achieving substa

0 views • 73 slides

Explore the effective medication treatments for opioid addiction, including buprenorphine, naltrexone, and methadone. Learn about the importance of maintenance therapy, long-term benefits, and key considerations in managing opioid use disorder. This guide covers pharmacotherapy options, treatment pr

0 views • 23 slides

Developmental pharmacology in children involves unique considerations such as drug metabolism, urine concentration, and muscle relaxant dosing. The field faces challenges with limited drug testing in pediatric populations, emphasizing the importance of age-appropriate pharmacotherapy. Factors like d

0 views • 39 slides

The NHS Long-Term Plan aims to provide smoking cessation support to all inpatients, including those in mental health settings. The East London NHS Foundation Trust (ELFT) is implementing the Ottawa model to help MH inpatients quit smoking. The ELFT's early implementation pilot focuses on systematic

0 views • 7 slides